New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
Johnson & Johnson reported Phase 3 MonumenTAL-3 results for TALVEY (talquetamab-tgvs) plus DARZALEX FASPRO (daratumumab/hyaluronidase) with or without pomalidomide in relapsed/refractory multiple myeloma. Compared with DPd, PFS at 24 months was up to 81.3% vs 51.2% and OS up to 89.2% vs 79.1%. The company said hazard ratios for PFS were 0.28 (Tal-DP) and 0.33 (Tal-D).
Positive Phase 3 readout for an earlier-line GPRC5D bispecific combo increases probability of regulatory progress and strengthens the multiple myeloma pipeline narrative.
Johnson & Johnson announced Phase 3 MonumenTAL-3 results for TALVEY plus DARZALEX FASPRO, showing improved PFS/OS vs DPd and filed for FDA/EMA review.
Likely supportive for JNJ sentiment and biotech read-through, though magnitude depends on how the market prices future FDA/label timing.
Background
MonumenTAL-3 is described as the first Phase 3 study showing superior PFS for a GPRC5D bispecific combination in earlier-line multiple myeloma, with results presented at EHA and published in NEJM.
Why it matters
The disclosed hazard ratios, 24-month PFS/OS rates, and safety comparisons versus DPd provide a concrete efficacy signal, while the stated sBLA/EMA submissions create a regulatory catalyst path for traders to monitor.
Market relevance
Traders get a fresh, detailed Phase 3 efficacy/safety dataset plus explicit FDA/EMA filing intent, which can move expectations for future multiple myeloma treatment sequencing and approval timelines.
Market effects
Reinforces the competitive shift toward earlier-line bispecific combinations in multiple myeloma, potentially raising expectations for other GPRC5D/BCMA-agnostic strategies.
Primarily US/Europe regulatory and conference-driven sentiment (FDA/EMA filings; EHA presentation).
Could influence global myeloma treatment sequencing discussions and investor positioning across large-cap oncology portfolios.
Alternative perspectives
Despite strong efficacy, the market may discount near-term impact until FDA label timing, confirmatory endpoints, and longer follow-up validate durability and safety tradeoffs.
The article notes GPRC5D expression on some healthy cells and reports infection rates and CRS frequency; investors may focus on subgroup outcomes, real-world tolerability, and how pomalidomide affects adoption.
Key entities
- companyJohnson & Johnson
Sponsor of the MonumenTAL-3 Phase 3 study evaluating TALVEY plus DARZALEX FASPRO with or without pomalidomide in RRMM.
- drugTALVEY (talquetamab-tgvs)
GPRC5D bispecific antibody used in combination regimens in MonumenTAL-3.
- drugDARZALEX FASPRO (daratumumab and hyaluronidase-fihj)
Anti-CD38 therapy used as the backbone comparator/combination partner in MonumenTAL-3.
- clinical_trialMonumenTAL-3 (NCT05455320)
Randomized Phase 3 trial comparing TALVEY+DARZALEX FASPRO (± pomalidomide) versus DPd in RRMM after ≥1 prior line.
